Upexi (NASDAQ:UPXI) Earns Buy Rating from Analysts at Alliance Global Partners

Key Points

• Analysts at Alliance Global Partners have initiated coverage on Upexi (NASDAQ:UPXI), assigning a "buy" rating and a price target of $15.00, indicating a potential upside of 226.09%.
• Upexi's stock recently opened at $4.60 and has fluctuated between a 1-year low of $1.90 and a 1-year high of $22.57.
• Significant insider transactions were noted, including purchases by Director Lawrence Dugan and CEO Allan Marshall, increasing their ownership stakes in the company.

Investment analysts at Alliance Global Partners assumed coverage on shares of Upexi (NASDAQ:UPXI - Get Free Report) in a research note issued on Monday,Briefing.com Automated Import reports. The brokerage set a "buy" rating and a $15.00 price target on the stock. Alliance Global Partners' price objective points to a potential upside of 226.09% from the stock's previous close.

A number of other equities analysts also recently weighed in on the stock. Wall Street Zen raised shares of Upexi to a "hold" rating in a research note on Friday, May 30th. Cantor Fitzgerald upgraded shares of Upexi from a "neutral" rating to an "overweight" rating and set a $16.00 price objective for the company in a report on Monday, June 16th.

Upexi Stock Down 0.9%

NASDAQ UPXI opened at $4.60 on Monday. Upexi has a 1-year low of $1.90 and a 1-year high of $22.57. The company has a quick ratio of 0.24, a current ratio of 0.37 and a debt-to-equity ratio of 0.31. The firm's fifty day simple moving average is $7.42 and its 200-day simple moving average is $6.00.

Upexi (NASDAQ:UPXI - Get Free Report) last posted its quarterly earnings results on Friday, May 16th. The company reported ($2.87) earnings per share for the quarter. Upexi had a negative return on equity of 535.19% and a negative net margin of 135.86%. The company had revenue of $3.16 million during the quarter.

Insider Buying and Selling

In other Upexi news, Director Lawrence Dugan acquired 4,000 shares of the firm's stock in a transaction that occurred on Tuesday, July 22nd. The stock was purchased at an average cost of $7.50 per share, for a total transaction of $30,000.00. Following the completion of the acquisition, the director owned 116,389 shares of the company's stock, valued at approximately $872,917.50. This trade represents a 3.56% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Allan Marshall acquired 161,943 shares of the firm's stock in a transaction that occurred on Friday, July 11th. The stock was acquired at an average price of $4.94 per share, with a total value of $799,998.42. Following the completion of the acquisition, the chief executive officer directly owned 1,046,261 shares of the company's stock, valued at $5,168,529.34. This represents a 18.31% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 198,186 shares of company stock worth $997,759. Corporate insiders own 31.60% of the company's stock.

Institutional Investors Weigh In On Upexi

A number of hedge funds have recently bought and sold shares of the company. Bank of Montreal Can bought a new stake in Upexi during the fourth quarter valued at about $36,000. North Star Investment Management Corp. bought a new stake in Upexi during the second quarter valued at about $45,000. Finally, Kathmere Capital Management LLC bought a new stake in Upexi during the second quarter valued at about $6,535,000. 5.68% of the stock is currently owned by institutional investors.

About Upexi

Upexi, Inc manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc and changed its name to Upexi, Inc in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.